Literature DB >> 24892624

Controlled release effervescent buccal discs of buspirone hydrochloride: in vitro and in vivo evaluation studies.

A Jaipal1, M M Pandey1, S Y Charde2, N Sadhu1, A Srinivas1, R G Prasad1.   

Abstract

In the present study controlled release effervescent buccal discs of buspirone hydrochloride (BS) were designed using HPMC as rate controlling and bioadhesive polymer by direct compression method. Sodium bicarbonate and citric acid were used in varying amounts as effervescence forming agents. Carbon dioxide evolved due to reaction of sodium bicarbonate and citric acid was explored for its potential as buccal permeation enhancer. The designed buccal discs were evaluated for physical characteristics and in vitro drug release studies. Bioadhesive behavior of designed buccal discs was assessed using texture analyzer. In vivo animal studies were performed in rabbits to study bioavailability of BS in the designed buccal discs and to establish permeation enhancement ability of carbon dioxide. It was observed that effervescent buccal discs have faster drug release compared to non-effervescent buccal discs in vitro and effervescent buccal discs demonstrated significant increase in bioavailability of drug when compared to non-effervescent formulation. Hence, effervescent buccal discs can be used as an alternative to improve the drug permeation resulting in better bioavailability. However, the amount of acid and base used for generation of carbon dioxide should be selected with care as this may damage the integrity of bioadhesive dosage form.

Entities:  

Keywords:  Buccal discs; buspirone hydrochloride; drug delivery; effervescent; pharmacokinetics

Mesh:

Substances:

Year:  2015        PMID: 24892624     DOI: 10.3109/10717544.2014.917388

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  7 in total

1.  A One-Step Twin-Screw Melt Granulation with Gelucire 48/16 and Surface Adsorbent to Improve the Solubility of Poorly Soluble Drugs: Effect of Formulation Variables on Dissolution and Stability.

Authors:  Sandeep Sarabu; Venkata Raman Kallakunta; Arun Butreddy; Karthik Yadav Janga; Srinivas Ajjarapu; Suresh Bandari; Feng Zhang; S Narasimha Murthy; Michael A Repka
Journal:  AAPS PharmSciTech       Date:  2021-02-19       Impact factor: 3.246

2.  Chrono modulated multiple unit particulate systems (MUPS) via a continuous hot melt double extrusion technique: Investigation of the formulation and process suitability.

Authors:  Venkata Raman Kallakunta; Sandeep Sarabu; Narendar Dudhipala; Karthik Yadav Janga; Suresh Bandari; Feng Zhang; Michael A Repka
Journal:  Eur J Pharm Biopharm       Date:  2021-08-28       Impact factor: 5.571

3.  Effect of HPMC and mannitol on drug release and bioadhesion behavior of buccal discs of buspirone hydrochloride: In-vitro and in-vivo pharmacokinetic studies.

Authors:  A Jaipal; M M Pandey; S Y Charde; P P Raut; K V Prasanth; R G Prasad
Journal:  Saudi Pharm J       Date:  2014-12-08       Impact factor: 4.330

4.  Risperidone mucoadhesive buccal tablets: formulation design, optimization and evaluation.

Authors:  Burak Çelik
Journal:  Drug Des Devel Ther       Date:  2017-11-27       Impact factor: 4.162

5.  Buccal Buspirone as add-on Therapy to Omeprazole Versus Omeprazole in Treatment of Gastroesophageal Reflux Diseases (GERD).

Authors:  Saeed Abdi; Zahra Sargashteh; Mohammad Abbasinazari; Jamshid Salamzadeh; Seyed Alireza Mortazavi
Journal:  Iran J Pharm Res       Date:  2020       Impact factor: 1.696

6.  Improvements in sticking, hygroscopicity, and compactibility of effervescent systems by fluid-bed coating.

Authors:  Xiao Zheng; Fei Wu; YanLong Hong; Lan Shen; Xiao Lin; Yi Feng
Journal:  RSC Adv       Date:  2019-10-04       Impact factor: 4.036

7.  Development of Mucoadhesive Buccal Film for Rizatriptan: In Vitro and In Vivo Evaluation.

Authors:  Anroop B Nair; Jigar Shah; Shery Jacob; Bandar E Al-Dhubiab; Vimal Patel; Nagaraja Sreeharsha; Pottathil Shinu
Journal:  Pharmaceutics       Date:  2021-05-15       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.